Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | Real-world outcomes by co-mutation status in KRAS G12C-mutant NSCLC

Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a retrospective study analyzing co-mutations in patients with KRAS G12C-mutatnt non-small cell lung cancer (NSCLC) receiving sotorasib or adagrasib. STK11 or KEAP1 co-mutations were associated with worse outcomes, and mutations in the PI3K/mTOR pathway such as TSC1 and TSC2 gene mutations were additionally associated with poorer survival. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.